Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

Veritas China USD A

Ranked 3 out of 10 in - Emerging Market Equity Including Asia over 12 months
All calculations are in USD unless stated

Managed by

Ezra Sun

Ezra Sun is someone who pursues independent themes and is not afraid to follow his convictions. Sun describes his style as global thematic and draws on regional specialists to fine-tune his decisions. He manages the Veritas Asian fund, having joined Veritas Asset Management (UK) Ltd from Newton Investment Management in 2004. He joined Newton as an Asia-Pacific equities analyst in 1995, and is currently a director, fund manager and head of Far East at Veritas. Born in 1967, Sun is fluent in Chinese and holds a degree in English Literature from Nankai University, China. He was also a research student at Cambridge University.


The investment objective of Veritas China Fund is to achieve long term capital growth, regardless of market conditions, by taking long and short positions primarily in equities or equity related derivative contracts of companies located in China (People's Republic Of China, and its Specials Administrative Regions, Hong Kong and Macau) or companies that are not located in China but derive a majority (over 50%) of their income from China.

Showing fund performance in Malta View performance globally


Emerging Market Equity Including Asia over : 31/08/2017 - 31/08/2018
  • Rank 3/10 Total Return
  • Rank 7/10 Standard Deviation
  • Rank 6/10 Max Drawdown
Fund Name Currency Risk
5 OAKS Emerging and Frontier Opps C USD

Currency exposure is hedged

Currency exposure is hedged



6 Schroder ISF Asian Total Return A Acc USD


7 Veritas China USD A USD


8 BSF Emerging Markets Absolute Return D2 USD USD


9 LBN China+ Opportunity UCITS I (USD) USD


Fund Name Currency Loss
4 Allianz Market Neutral Asian Equity - I - USD USD


5 Lyxor / Capricorn Gem Strategy Fund I USD Acc USD


6 Veritas China USD A USD


7 Schroder ISF Asian Total Return A Acc USD


8 OAKS Emerging and Frontier Opps C USD

Currency exposure is hedged

Currency exposure is hedged



Total Return

Quarterly Performance

to 30/06/2018 Annual Q1 Q2 Q3 Q4
2018 2.1% 1.8%
2017 31.0% 10.9% 3.7% 9.3% 4.2%
2016 -19.6% -11.5% -4.8% 5.3% -9.3%
2015 6.5% 4.0% 11.6% -9.6% 1.5%
2014 -0.8% -5.2% 2.5% 0.0% 2.2%
2013 22.0% 6.2% 0.9% 3.5% 10.0%
2012 13.9% 0.7% 0.3% 1.0% 11.6%
2011 -18.7% -2.7% -0.1% -10.6% -6.4%
2010 12.3% 1.3% -2.7% 8.9% 4.7%

Month by Month Performance

Returns Vs Risk

Asset Allocation



Top 10 Holdings

Stock Size
CSPC Pharmaceutical Group Ltd ORD 5.17%
Jiangsu Hengrui Medicine Co Ltd ORD 4.62%
China Biologic Products Holdings Inc ORD 4.49%
Beigene Ltd DR 4.17%
AIA Group Ltd ORD 3.84%
Shanghai Fosun Pharmaceutical Group Co Ltd ORD 3.78%
Midea Group Co Ltd ORD 3.69%
Hangzhou Hikvision Digital Technology Co Ltd ORD 3.35%
Shenzhou International Group Holdings Ltd ORD 2.70%
Ctrip.Com International Ltd 1.250% 15-Sep-2022 2.52%

Registered For Sale In

  1. Ireland
  2. Switzerland
  3. United Kingdom

Fund Info

  • Launch date02/10/2009
  • Share Class size22Mn
  • Base currencyUSD

Purchase Info

  • Min. initial investment50,000
  • Min. regular additional investment0


  • Annual management1.00%
  • Initial investment0.00%

Related News

Euro Star of the Day: Ezra Sun, Veritas Asset Management

Citywire Selector showcases the top 250 managers on a risk-adjusted basis.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).